RhumbLine Advisers
FDMT icon

RhumbLine Advisers’s 4D Molecular Therapeutics FDMT Stock Holding History

RhumbLine Advisers’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$793K Buy
59,638
+5,537
+10% +$53.9K ﹤0.01% 2470
2026
Q1 		$504K Buy
54,101
+256
+0.5% +$2.23K ﹤0.01% 2609
2025
Q4 		$404K Sell
53,845
-10,334
-16% -$105K ﹤0.01% 2796
2025
Q3 		$558K Sell
64,179
-1,779
-3% -$10.6K ﹤0.01% 2626
2025
Q2 		$245K Sell
65,958
-4,845
-7% -$17K ﹤0.01% 3114
2025
Q1 		$229K Sell
70,803
-2,628
-4% -$12.4K ﹤0.01% 3040
2024
Q4 		$409K Buy
73,431
+3,675
+5% +$28.8K ﹤0.01% 2794
2024
Q3 		$754K Sell
69,756
-3,177
-4% -$52.7K ﹤0.01% 2422
2024
Q2 		$1.53M Buy
72,933
+9,062
+14% +$227K ﹤0.01% 2023
2024
Q1 		$2.03M Buy
63,871
+3,950
+7% +$101K ﹤0.01% 1909
2023
Q4 		$1.21M Buy
59,921
+1,472
+3% +$19.4K ﹤0.01% 2154
2023
Q3 		$744K Buy
58,449
+9,461
+19% +$158K ﹤0.01% 2372
2023
Q2 		$885K Buy
48,988
+1,487
+3% +$27.4K ﹤0.01% 2360
2023
Q1 		$817K Buy
47,501
+58
+0.1% +$1.13K ﹤0.01% 2219
2022
Q4 		$1.05M Buy
47,443
+2,070
+5% +$32K ﹤0.01% 2106
2022
Q3 		$365K Buy
45,373
+3,788
+9% +$34.3K ﹤0.01% 2637
2022
Q2 		$290K Buy
41,585
+6,488
+18% +$63.1K ﹤0.01% 2773
2022
Q1 		$531K Buy
35,097
+4,382
+14% +$68.8K ﹤0.01% 2400
2021
Q4 		$674K Buy
30,715
+6,177
+25% +$151K ﹤0.01% 2384
2021
Q3 		$662K Buy
24,538
+15,031
+158% +$429K ﹤0.01% 2425
2021
Q2 		$229K Buy
9,507
+3,651
+62% +$112K ﹤0.01% 2887
2021
Q1 		$254K Buy
+5,856
New +$259K ﹤0.01% 2755

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

RhumbLine Advisers's FDMT Position: Q2 2026 in Review

RhumbLine Advisers increased its 4D Molecular Therapeutics (FDMT) stake by 10% in Q2 2026, buying an estimated $53.9K and bringing the position to 59,638 shares worth $793K. The position accounts for ﹤0.01% of the portfolio, ranked #2470.

RhumbLine Advisers first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $2.03M in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • RhumbLine Advisers held 59,638 shares of 4D Molecular Therapeutics worth $793K as of Q2 2026.
  • RhumbLine Advisers bought 5,537 4D Molecular Therapeutics shares in Q2 2026, an estimated $53.9K.
  • 4D Molecular Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2470 holding.
  • RhumbLine Advisers first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • RhumbLine Advisers's 4D Molecular Therapeutics position peaked at $2.03M in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.